SLC5A2 and diabetes mellitus: The EMPA-REG OUTCOME trial of empagliflozin was the first large-scale placebo-controlled cardiovascular outcome trial to report the effects of an SGLT-2 inhibitor in type 2 diabetes mellitus (DM) [14].